AKB-9778
Sponsors
Aerpio Therapeutics, EyePoint Pharmaceuticals, Inc.
Conditions
Diabetic Macular Edema (DME)Nonproliferative Diabetic RetinopathyRetinal Vein Occlusion
Phase 2
The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema
CompletedNCT02050828
Start: 2014-01-31End: 2015-05-31Updated: 2017-03-16
Open Label Study to Assess the Efficacy and Safety of AKB-9778 in Subjects With Macular Edema Due to RVO
CompletedNCT02387788
Start: 2015-01-31End: 2017-04-30Updated: 2018-06-27
The TIME-2b Study: A Study of AKB-9778 (Razuprotafib), a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)
CompletedNCT03197870
Start: 2017-06-09End: 2019-02-09Updated: 2023-06-27